Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 5,964

Document Document Title
WO/2016/030443A1
Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  
WO/2016/025364A1
The present invention provides a novel synthesis of verubecestat, and two novel crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliora...  
WO/2016/025632A1
The present invention relates to new semiconducting compounds having at least one optionally substituted benzo[d][1,2,3]thiadiazole moiety. The compounds disclosed herein can exhibit high carrier mobility and/or efficient light absorptio...  
WO/2016/015593A1
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or ...  
WO/2015/196258A1
The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosur...  
WO/2015/199987A1
A compound of Formula (I). In this formula, each of R1, R2, R3, R4, R5, R6, R7, L1, L2, L3, W, X, Y, and Z is defined herein. Also disclosed are a composition containing a compound of Formula (I) and a method for enhancing the sweet tast...  
WO/2015/196071A9
The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features method...  
WO/2015/196071A1
The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features method...  
WO/2015/191630A1
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.  
WO/2015/163817A1
A fluorophore or conjugated polymer with aggregation-induced emission characteristics useful for drug tracking and delivery, identification and labeling of biological subjects, such as cells or parts of a cell, as well as for imaging, an...  
WO/2015/159098A1
There are provided compounds of the formula D-S1-A-S2-B1 wherein A comprises a 2,7- disubstituted 9,9-fluoroalkyl fluorene diradical of the formula wherein S1, S2, D and B1 have meanings given in the description that are useful as charge...  
WO/2015/156417A1
The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases ...  
WO/2015/157382A1
This disclosure relates to asparagine endopeptidase inhibitors and compositions and uses related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are useful for treating or preventing neurodegenerative diseases an...  
WO/2015/150824A1
The invention relates to compounds in the treatment or prevention of disorders associated with Lamin A and/or Lamin C depletion or LMNA mutations, such as laminopathy, premature ageing disorders, normal ageing and cancer(such as a cancer...  
WO/2015/143653A1
The present invention is directed to substituted five membered heteroaryl benzamide compounds compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of...  
WO/2015/143652A1
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, ...  
WO/2015/143652A8
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, ...  
WO/2015/138869A1
The present disclosure provides new materials that combine the advantages of well-defined polymeric starting materials and the convenience of surface modification by physical methods into one package and, thus, offers a general and power...  
WO/2015/125085A1
The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, geometrical isomer, prodrug, carboxylic acid isostere, solvate, polymorph, N-oxide, S-oxide or pharmaceutically acceptable salt thereof, which are G...  
WO/2015/108136A1
The present invention provides: a novel α-substituted glycinamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the compound or the pharmacologically acceptable salt; and a use of the...  
WO/2015/107541A1
The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use ...  
WO/2015/104433A1
The invention relates to benzo[c][1,2,5]oxadiazole derivatives, and the use thereof as antibiotics and in particular for the treatment and/or prevention of diseases caused by bacteria, in particular of diseases caused by Helicobacter.  
WO/2015/101958A2
The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or d...  
WO/2015/101957A3
The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or d...  
WO/2015/101958A3
The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or d...  
WO/2015/100441A1
Disclosed are conjugated polymers having desirable properties as semiconducting materials. Such polymers are cheap and easy to synthesize, and can exhibit good solubility and great solution processibility, and that enable highly efficien...  
WO/2015/094930A1
In its many embodiments, the present invention provides certain C-6 spirocarbocyclic iminothiadiazine compounds, including compounds Formula (I): or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said ta...  
WO/2015/074180A1
Disclosed is a method for preparing thiadiazolylamide compounds. 2-sulfinyl-5-(trifluoromethyl)-1,3,4-thiadiazole (II) and 2-sulfuryl--5- (trifluoromethyl)-1,3,4-thiadiazole (II') are mixed in mass ratio of 99:1-1:99 as mixed raw materia...  
WO/2015/033303A1
The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The i...  
WO/2015/033301A1
The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also refers to derivatives of the therapeut...  
WO/2015/033299A1
The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeuti...  
WO/2015/031109A1
Compounds, or pharmaceutically acceptable salts or esters thereof, having a structure of: wherein each of R1-R5 is individually selected from H, halogen, optionally substituted alkyl, optionally substituted alkoxy, nitro, sulfonamide, hy...  
WO/2015/031109A8
Compounds, or pharmaceutically acceptable salts or esters thereof, having a structure of: wherein each of R1-R5 is individually selected from H, halogen, optionally substituted alkyl, optionally substituted alkoxy, nitro, sulfonamide, hy...  
WO/2015/016442A1
The present invention relates to a novel phenylthiazole-based hydroxamic acid compound and an anti-cancer composition containing same as an active ingredient. A hydroxamic acid compound according to the present invention exhibits anti-ca...  
WO/2015/006100A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2014/181137A1
The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.  
WO/2014/173904A1
The present invention relates to compounds of formula (I) and their uses. In particular, though not exclusively, it concerns heterocyclic compounds that inhibit the biogenesis of adhesive pili in Gram- negative bacteria, and their use in...  
WO/2014/170793A1
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new s...  
WO/2014/161516A1
A substituted diazole of genera l formula (1) wherein X is 0 or S; R is selected from the group consisting of: H, NH2-, C1-C11n alkyl, cyclohexyl-, benzyl-, phenyl-, pyridyl- or phenyl- substituted, in positions 2, 3, 4 or 5, by one or m...  
WO/2014/157653A1
The present invention addresses the problem of providing an efficient process for preparing important intermediate compounds (1) and (1a) for the production of FXa inhibitors (X) and (X-a). The present invention pertains to: a process wh...  
WO/2014/156553A1
A purpose of the present invention is to provide a new disulfide compound with excellent compatibility toward polymers containing fluorine and solutions containing fluorine. The compound of the present invention is a compound expressed b...  
WO/2014/157497A1
An organic photoelectric conversion element which is provided with a first electrode, a photoelectric conversion layer that contains a compound represented by formula (I), and a second electrode; an organic thin film solar cell; a compos...  
WO/2014/150340A1
In its many embodiments, the present invention provides provides certain S-imino-S-oxo iminothiadiazine compounds, including compounds Formula (I): or a tautomers and/or stereoisomers thereof, and pharmaceutically acceptable salts of sai...  
WO/2014/146275A1
The present invention relates to a method for synthesizing a thiadiazole sulfoxide compound. Steps thereof comprise: thiadiazole thioether reacting in an organic solvent or mixed liquor of an organic solvent and water, by using a specifi...  
WO/2014/153100A3
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity. Methods ...  
WO/2014/147021A3
The present invention relates to substituted N-(phenyl-heteroaryl) -3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing sai...  
WO/2014/152588A1
Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.  
WO/2014/140059A1
Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, X5, X6, Y, Z, G, R1a, R2a, R1b, R2b, R3, R4, R5 and R6 are as defined herein. Also disclosed are methods of making the co...  
WO/2014/138833A1
The present invention describes new compounds for binding and/or inhibiting enzymes in microorganisms. In one embodiment, the compounds of the present invention are used to inhibit the 2-trans-enoyl-ACP (CoA) reductase enzyme in microorg...  
WO/2014/136099A1
The present invention relates to a novel process of making ixabepilone, ixabepilone derivatives and analogues, and intermediates thereof.  

Matches 101 - 150 out of 5,964